Active, Not Recruiting
Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH) - IM025-017
Updated:
9 January, 2024
|
ClinicalTrials.gov
Phase
Gender(s)
Age Range
Active, Not Recruiting
Inclusion Criteria: - Participants with liver biopsy fibrosis score stage 4 (NASH CRN) performed within 12 months - Men and women must agree to follow methods of contraception Exclusion Criteria: - Worsening liver disease or any disease might compromise participant safety in the opinion of the investigator - Known immunocompromised status or any disease or condition which might compromise participant safety - Prior exposure to BMS-986263 - Clinically relevant abnormal physical examination, vital signs, ECG, or clinical laboratory tests - Hepatic decompensation Other protocol-defined inclusion/exclusion criteria apply
If you want to report a side effect, you can report directly to the Danish Medicines Agency via the website www.meldenbivirkning.dk
We recommend that you also contact BMS to report side effects.
Side effects and other reportable events are defined here
Report side effects or product quality complaints: Medical Information
466-DK-2200001